Featured Clinical Trials Supported by the National Cancer Institute
Today, thousands of cancer clinical trials are under way in the United States. Clinical trials answer vital research questions that lead to better screening, prevention, diagnosis, and treatment options for all cancers. This section highlights NCI-supported cancer trials and demonstrates the breadth of clinical cancer research supported by the Institute.
To find other cancer trials open to enrollment:
- Call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for information about trials all across the country. The call is toll-free and completely confidential.
- Use the clinical trials search form to look online for trials listed on NCI's Cancer.gov Web site. The form has a Help link for tips about searching for clinical trials.
- For information about cancer trials taking place on the National Institutes of Health campus in Bethesda, Maryland, call NCI’s Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937). The call is toll-free and completely confidential.
(Posted: 10/19/2010) - In this trial, patients with hairy cell leukemia who have disease-related symptoms that require treatment, and who have not been treated or have had only one prior treatment with cladribine, will be randomly assigned to receive cladribine with either concurrent rituximab or rituximab at least 6 months after completing cladribine therapy.
Combination Therapy for Head and Neck Cancer
(Posted: 03/23/2004, Updated: 10/14/2010) - No standard therapy currently exists for head and neck cancer that recurs after treatment with radiation. Laboratory studies have shown that bortezomib (Velcade), a new type of cancer drug called a proteasome inhibitor, inhibits growth of head and neck cancer cells. This clinical study is the first test of whether bortezomib can increase the effectiveness of repeat radiation treatment for patients whose head and neck cancer has recurred.
Preventing Chemotherapy-Related Hearing Loss in Young Cancer Patients
(Posted: 10/05/2010) - In this clinical trial, children and adolescents with cancer who are scheduled to receive cisplatin will be randomly assigned to receive sodium thiosulfate intravenously 6 hours after each cisplatin infusion or no additional treatment after each cisplatin infusion.
Biological Therapy to Treat Kaposi Sarcoma
(Posted: 08/03/2004, Updated: 09/23/2010) - Researchers with this study are investigating whether bevacizumab (Avastin®), a type of biological agent that blocks the formation and growth of new blood vessels, is effective in the treatment of Kaposi sarcoma (KS). Blood vessel cells are the main component of KS lesions.
Combining Vaccine and Antiandrogen Therapy for Prostate Cancer
(Posted: 09/21/2010) - In this clinical trial, men with castration-resistant, nonmetastatic prostate cancer who are undergoing androgen deprivation therapy will be randomly assigned to undergo antiandrogen treatment with the FDA-approved drug flutamide with or without the addition of a PSA-targeting vaccine called PROSTVAC/PSA-TRICOM.